|
BIOVAIL CORP, (BVF) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Biovail Corporation engages in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products for the treatment of chronic medical conditions primarily in North America. Its primary focus is on the therapeutic areas, such as cardiovascular disease, central nervous system disorders, and pain management, Type II diabetes, and antiviral medicines. Biovail focuses on the development, manufacture, and sale of branded pharmaceutical products incorporating its advanced proprietary drug delivery technologies. The companys products are commercialized in various countries through licensing agreements with strategic marketing partners, with the primary market being the United States. Products are marketed directly by the companys sales and marketing divisions in the United States and Canada or through manufacturing, supply, and license agreements with third party pharmaceutical companies in the United States and world markets. It also promotes and/or co-promotes products on behalf of third parties; provides research, development, and clinical contract research services to third parties; and sells its controlled release products through third parties. Biovail was established in 1994 with the amalgamation of Trimel Corporation and its subsidiary Biovail Corporation International. The company was formerly known as Biovail Corporation International and changed its name to Biovail Corporation in 2000. The company is headquartered in Mississauga, Canada.
|
BIOVAIL CORP Related |
|
Biovail Pharmaceuticals Engaged in the formulation, clinical testing, registration, manufacture, sale, and promotion of pharmaceutical products utilizing advanced drug delivery technologies.
|
|
Biovail Corporation: Information from Answers.com Biovail Corporation (NYSE:BVF) (Toronto:BVF) Company Financials Income Statement Balance Sheet Cash Flow ... Biovail. 1993: Melnyk merges Trimel Corp. with ...
|
|
home About Biovail. Investor Relations. Products. New Strategic Focus. Careers. See News Archive ... Biovail Announces Filing of ANDA for Quetiapine XR Tablets. 11 ...
|
|
